Prescription Drugs - Australia

Australia

The Prescription Drugs market in Australia is projected to reach a revenue of AU €11.34bn in 2024.
It is expected to show an annual growth rate (CAGR 2024-2029) of 4.51%, resulting in a market volume of AU €14.14bn by 2029.
In comparison to other countries, United States is expected to generate the highest revenue in the Prescription Drugs market, with €332.90bn in 2024.
When considering the population, the per person revenue in Australia is estimated to be AU €0.42k in 2024.
Australia's pharmaceutical market is seeing a surge in demand for prescription drugs due to an aging population and increased chronic disease prevalence.

Key regions: Japan, China, Europe, Australia, Canada

Marché

Région

Comparaison de régions

Monnaie

Analyst Opinion

The Prescription Drugs (Pharmacies) market in Australia is experiencing significant growth due to several key factors.

Customer preferences: Customers in Australia have a strong preference for accessing prescription drugs through pharmacies. This is primarily driven by the convenience and accessibility that pharmacies offer. Pharmacies are easily accessible in both urban and rural areas, providing customers with a convenient location to fill their prescriptions. Additionally, pharmacies often offer a wide range of healthcare services, such as medication counseling and health screenings, which further attract customers.

Trends in the market: One of the key trends in the Prescription Drugs (Pharmacies) market in Australia is the increasing demand for generic drugs. Generic drugs are more affordable than brand-name drugs, making them a popular choice among customers. This trend is driven by the rising healthcare costs in Australia and the government's efforts to promote the use of generic drugs to reduce healthcare expenditure. As a result, pharmacies are expanding their offerings of generic drugs to meet the growing demand. Another trend in the market is the growing focus on personalized medicine. Customers are increasingly seeking customized treatment options that are tailored to their specific needs. Pharmacies are responding to this trend by offering personalized medication compounding services, where medications are specially formulated to meet individual patient requirements. This allows pharmacies to differentiate themselves in the market and attract customers who are looking for personalized healthcare solutions.

Local special circumstances: Australia has a unique healthcare system that plays a significant role in the development of the Prescription Drugs (Pharmacies) market. The country has a universal healthcare system called Medicare, which provides subsidized healthcare services to all Australian residents. This system ensures that prescription drugs are accessible and affordable to a large portion of the population, driving the demand for pharmacies. Additionally, the aging population in Australia is contributing to the growth of the Prescription Drugs (Pharmacies) market. As the population ages, there is an increased need for prescription medications to manage chronic conditions and age-related health issues. Pharmacies are well-positioned to cater to this growing demand and provide the necessary medications and healthcare services to the aging population.

Underlying macroeconomic factors: The strong economic growth in Australia is fueling the development of the Prescription Drugs (Pharmacies) market. A growing economy means increased disposable income, allowing customers to spend more on healthcare, including prescription drugs. This, in turn, drives the demand for pharmacies and their products and services. Furthermore, the government's focus on healthcare and pharmaceutical industry development is also contributing to the growth of the market. The government has implemented various policies and initiatives to support the pharmacy sector, such as increasing funding for community pharmacies and promoting the use of generic drugs. These measures create a favorable business environment for pharmacies and encourage their growth and expansion. In conclusion, the Prescription Drugs (Pharmacies) market in Australia is experiencing growth due to customer preferences for convenient access to prescription drugs and the increasing demand for generic and personalized medications. The country's unique healthcare system, aging population, strong economic growth, and government support further contribute to the development of the market.

Methodology

Data coverage:

The data encompasses B2C enterprises. Figures are based on offline and online spending by consumers, including VAT. Not included are B2B and B2G sales, or other pharmaceutical sales through hospitals or retail stores such as supermarkets.

Modeling approach:

Market sizes are determined through a bottom-up approach, building on specific predefined factors for each market market. As a basis for evaluating markets, we use industry associations, third-party studies and reports and survey results from our primary research (e.g., the Statista Global Consumer Survey). In addition, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per country, consumer healthcare spending, GDP and internet penetration. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the relevant market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. For forecasting digital trends such as the online-pharmacy sales share we use exponential trend smoothing and the s-curve method. The main drivers are healthcare expenditure per country and consumer healthcare spending.

Additional notes:

The data is modeled using current exchange rates. The impact of the COVID-19 pandemic and the Russia-Ukraine war are considered at a country-specific level. The market is updated twice a year. GCS data is reweighted for representativeness.